Harnessing peptide conjugates strategies for cancer immunotherapy and infectious disease

“Early engagement with regulatory bodies is essential to clarify how peptide conjugates will be evaluated.” Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks to Helen Bright, CSO, Centauri Therapeutics, about an immune-stimulating platform that leverages peptide conjugation to enhance immune responses. She discusses the challenges and advantages of this conjugate platform, from achieving regulatory body approval to therapeutic efficacy. Bioconjugation Insights is the only digital content channel that truly provides the ‘big picture’ for this rapidly evolving and expanding field. If you would like to access all of our Open Access content, you can register here.